home > pmps > winter 2020 > an exercise in quality risk management
Pharmaceutical Manufacturing and Packing Sourcer

An Exercise in Quality Risk Management

The terms extractable and leachable (E&L) have almost become a grammatical contraction for some, but this is a mistake. The terms are distinct and must not be blended into one. When fully understood, both are essential and complementary with different roles in quality risk management.

The Difference Between Extractables and Leachables

‘Extractable’, and its accompanying term ‘extractable study’, was coined to describe a wide number of experimental studies conducted on materials used in pharmaceutical packaging, devices, and manufacture to generate knowledge and understanding of the impurities found in these materials under study. Which system one chooses to study is directed by need and experience. This topic area of E&L was created from a realisation that the quality of the packaging system used in some dose forms was a potential contamination source for drug products, and thus a risk to patient safety.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:

There are no comments in regards to this article.

About the author

Jason Creasey recently set up Maven E&L to provide independent consultant advice in the area of E&L. He has worked in this topic area since the mid-1990s. Prior to setup, Jason was the Director of a team of analytical chemists providing GSK’s global R&D support for E&L activities. This included: biopharmaceutical and small molecules such as inhalation, parenteral, and cell and gene therapy use. He has been a member of several external groups concerned with best practice guides for E&L issues and continues as a scientific advisor to Extractable and Leachable Safety Information Exchange.
Print this page
Send to a friend
Privacy statement
News and Press Releases

3P Biopharmaceuticals initiates partnership with American Biotech Zhittya for Parkinson’s disease treatment

3P and Zhittya began their relationship at the beginning of 2019 with 3P being selected as the CDMO to transfer the process for scaling up and performing cGMP manufacturing for clinical studies. After successfully achieving transfer of the process, 3P anticipates manufacturing of the first cGMP batch by the second quarter of 2020.
More info >>

White Papers

Novo Nordisk Pharmatech A/S signs distribution agreement with DKSH for twelve countries in Asia Pacific.

Novo Nordisk Pharmatech A/S

Novo Nordisk Pharmatech A/S and DKSH, have partnered to provide high-quality cGMP quaternary ammonium compounds in twelve countries across Asia Pacific.
More info >>

Industry Events

World Vaccine Congress Washington

7-9 April 2020, Walter E Washington Convention Center, Washington, US

The World Vaccine Congress is an award-winning series of conferences and exhibitions that have grown to become the largest and most established vaccine meeting of its kind across the globe. Our credibility is show through the prestigious scientific advisory board that spend months of hard work creating a new and topical agenda, year on year.
More info >>



©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement